About Intellect Neurosciences, Inc.
Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in
the discovery and development of disease-modifying therapeutic agents for
the treatment and prevention of Alzheimer's disease and other disorders.
The company has a broad proprietary immunotherapy platform for both passive
and active immunization against Alzheimer's disease. Also, Intellect has
recently completed Phase I clinical trials for OXIGON(TM), a unique
antioxidant and anti-amyloid compound that has potential to treat
Alzheimer's disease and other disorders. For additional information, please
visit http://www.intellectns.com, or contact:
Elliot Maza, JD, CPA
President & Chief Financial Officer
Intellect Neurosciences, Inc.
7 West 18th Street, 9th Floor
New York, NY 10011, USA
Safe Harbor Statement Regarding Forward-Looking Statements
The statements in this release and oral statements made by
representatives of Intellect relating to matters that are not historical
facts (including without limitation those regarding future performance or
financial results, the timing or potential outcomes of research
collaborations or clinical trials, any market that might develop for any of
Intellect's product candidates and the sufficiency of Intellect's cash and
other capital resources) are forward- looking statements that involve risks
and uncertainties, including, but not limited to, the likelihood that
actual performance or results could materially differ, that future research
will prove successful, the likelihood that any product in the research
pipeline will receive regulatory approval
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved